在Leishmania infantum循环菌株中,可能选择抗和甲铁酸的交叉耐药性
Lorena Bernardo1,2, Ana Victoria Ibarra-Meneses3,4, Noelie Douanne3,4
1WHO Collaborating Centre for Leishmaniasis, Spanish National Center for Microbiology, Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
PLoS neglected tropical diseases
|February 29, 2024
概括
甲基 (MTX) 和 (Sb) 可以选择耐药的莱什马尼亚寄生虫. 这种交叉耐药性可能会危及在特有地区使用免疫抑制剂的内脏莱什曼病患者的治疗.
科学领域:
- 寄生虫学的寄生虫学
- 免疫学 免疫学 免疫学
- 药物耐药性 药物耐药性 药物耐药性
背景情况:
- 内脏莱什曼病 (VL) 治疗的成功取决于宿主免疫力和有效的药物.
- 免疫抑制患者,例如,在甲索特雷克萨特 (MTX),面临更高的VL风险和治疗挑战.
- 越来越多的抗微生物药物耐药性使得在特有地区的VL管理变得复杂.
研究的目的:
- 在Leishmania infantum中研究 (Sb) 和MTX之间的相互作用.
- 在临床Leishmania婴儿菌株中评估药物耐药性机制.
- 了解免疫抑制剂对抗莱什曼病药物疗效的影响.
主要方法:
- 研究了Sb和MTX对L.婴儿参考 (LiWT) 和临床菌株 (LiFS-A,LiFS-B) 的影响.
- 分析了反应性氧物种 (ROS) 生产和药物敏感性.
- 评估化蛋白质组以确定药物标和耐药性途径.
主要成果:
- 在LiWT中,Sb或MTX暴露增加了ROS和药物敏感性.
- LiFS-A显示了Sb敏感性,但MTX耐药性与高ROS保护.
- LiFS-B对Sb和MTX都表现出耐药性;蛋白质组分析显示了差异性的药物标丰富.
结论:
- 在现场可能存在Sb-MTX交叉耐药的Leishmania寄生虫.
- 在接受免疫抑制剂的患者中,抗莱什曼治疗的疗效可能会受到损害.
- 强调需要在VL治疗策略中考虑药物相互作用.
相关概念视频
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...